Mountain View, CA December 5, 2008 REGiMMUNE Corporation, a privately held biopharmaceutical company focused on developing technologies and products for immune disorders, will present preclinical data on the company's potential therapeutic treatment for Graft versus Host Disease (GvHD) at the American Society of Hematology Annual Meeting being held December 6 through 9 in San Francisco, California. REGiMMUNE is developing KRN7000 (RGI-2001) as a new immunosuppressant for GvHD associated with stem cell transplantation. Two posters will be presented at ASH on the evenings of Sunday December 7 and Monday December 8, respectively.
Sunday, December 7: 6:00 PM - 8:00 PM
Donor-Specific Tolerance Induction through Expansion of DCregs and Tregs by a Liposomal Formulation of KRN7000 (RGI-2001)
Monday, December 8: 5:30 PM - 7:30 PM
A Liposomal Formulation of KRN7000 (RGI-2001) Potently Reduces GvHD Lethality through the Expansion of CD4+Foxp3+ Regulatory T cells in Murine Models.
"We are delighted to present our progress on RGI-2001 development at the 50th ASH Annual Meeting," said Mr. Haru Morita, President and Chief Executive Officer, REGiMMUNE. "This is a great opportunity to provide an update on our pre-IND stage product candidate, RGI-2001, which is in a preclinical study for GvHD associated with bone marrow transplantation. The company is also developing RGI-2001 for solid organ transplantation. Our mission is to develop novel therapies for immune disorders including allergies, autoimmune diseases and transplantation. We believe the success of RGI-2001 will be the first demonstration of the promise of our proprietary technology and of the company's significant development capabilities."
|Contact: Debra Bannister|